Johnson & Johnson’s (J&J) Icotyde (icotrokinra) has been approved by the US FDA to treat moderate-to-severe plaque psoriasis (PsO) in both adults and paediatric patients. Icotyde, an interleukin-23 ...

Watch this oddly satisfying thick wax scrape that hits just right! From smooth peeling to clean finishes, this candle cleaning moment delivers pure ASMR satisfaction. Perfect for fans of relaxing, ...

Plaque psoriasis is a long-lasting skin condition that causes thick, scaly patches (plaques) on the skin. It happens when your immune system becomes overactive and speeds up the growth of skin cells.

Folks with severe plaque psoriasis often have to choose between convenient pills that don't work very well or highly effective injections that come with the hassle of needles. That trade-off may soon ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist, for the treatment of moderate-to-severe plaque psoriasis in ...

"I was very ashamed. I felt like everywhere people were judging me," Amber Dean tells PEOPLE, recalling when her symptoms were at their worst Courtesy of Amber Dean (2) A woman suffered from plaque ...

Johnson & Johnson said the FDA has approved its once-daily psoriasis pill Icotyde. Icotyde targets IL-23, rivaling best-selling shots Tremfya and Skyrizi. J&J hasn't announced how much Icotyde will ...

Johnson & Johnson has won U.S. Food and Drug Administration approval of its Icotyde treatment for certain patients with moderate-to-severe plaque psoriasis, a chronic autoimmune condition that causes ...

For plaque psoriasis patients whose disease does not adequately respond to topical treatments, the next choice of therapies is typically injectable drugs. FDA approval of a Johnson & Johnson drug ...

Johnson & Johnson (JNJ) on Wednesday announced that the U.S. Food and Drug Administration (FDA) approved its once-daily pill Icotyde, developed with Protagonist Therapeutics (PTGX), as a treatment for ...

Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the lucrative psoriasis market with a new approval for a much-anticipated daily ...